Completed Access to Information Requests

About this information

Search the summaries of completed Access to Information (ATI) requests to find information about ATI requests made to the Government of Canada after January 2020. If you find a summary of interest, you can request a copy of the records at no cost using the form below each summary. Requests made through this form are considered informal requests and are not subject to the same requirements as requests under the Access to Information Act (ATIA).

If you don’t find what you are looking for you can request additional government records under an institution’s control by contacting the institution’s Access to Information and Privacy Coordinator or by submitting a formal access to information request.

*All information provided will incorporate the necessary exemptions and exclusions as per the Access to Information Act and the Privacy Act.

Download datasets of the summaries of completed access to information requests.

Report Type

Organization

Disposition

Year

Month

Found 15011 record(s)

Req # A-2023-001298

All public records regarding the establishment and purpose of the Branch Executive Committee. All individuals and departments involved and who the panel reports to. How the Branch Executive Committee's decisions are reviewed.

Organization: Health Canada

14 page(s)
October 2024

Req # A-2024-000496

The most current status of the Abbreviated New Drug Submission (ANDS) seeking approval of a generic degarelix acetate product, which was accepted into review by Health Canada in January 2024: Inactive; Process; Process Hold; Withdrawn. If the status…

Organization: Health Canada

1 page(s)
October 2024

Req # A-2024-000497

Provide a screenshot of the status page for the Degarelix Acetate Abbreviated New Drug Submission (ANDS) on the Drug Submission Tracking System (DSTS) interface.

Organization: Health Canada

1 page(s)
October 2024

Req # A-2024-000623

For the time period — October 17, 2018, to December 31, 2023 — the general companion totals to the aggregate data requested under A-2024-000151. If possible, further disaggregate the data disclosed under A-2024-000151 relating to Part 11 according…

Organization: Health Canada

6 page(s)
October 2024

Req # A-2024-000634

Number of psilocybin access requests submitted and granted since January 2022 under the Special Access Program; Number of exemption requests submitted and granted under subsection 56(1) of the Controlled Drugs and Substances Act (between 2020-2022…

Organization: Health Canada

2 page(s)
October 2024

Req # A-2019-001550

Adverse Drug Reactions (ADRs). Report numbers: E2B_02720298, E2B_02734604, E2B_02734630, & E2B_02749506.

Organization: Health Canada

81 page(s)
October 2024

Req # A-2024-000240

Adverse Drug Reactions (ADRs). Report numbers: E2B_07049790, E2B_07046471.

Organization: Health Canada

332 page(s)
October 2024

Req # A-2024-000273

Adverse Drug Reaction (ADR). Report number: E2B_06689043.

Organization: Health Canada

178 page(s)
October 2024

Req # A-2024-000374

Briefing note in the Ministerial Executive Correspondence System (MECS) for the following file: 24-103258-616, The Governor General’s Symposium: Building a Safe and Respectful Digital World.

Organization: Health Canada

6 page(s)
October 2024

Req # A-2024-000447

Adverse Drug Reactions (ADRs). Report numbers: E2B_07160708, E2B_07185457.

Organization: Health Canada

288 page(s)
October 2024
Date modified: